High Fines for High Prices
UK company fined for massively hiking the price of a generic drug
Stephanie Sutton | | Quick Read
Advanz Pharma has been fined over £100 million by the UK’s Competition and Markets Authority (CMA) for charging “excessive and unfair” prices for tablets used to treat thyroid hormone deficiency (1). From 2007 to 2017, the price of liothyronine tablets in Britain rose by more than 6,000 percent. Once the prices became unsustainable for the UK’s National Health Service (NHS), the medicine was added to a “drop list,” leaving many patients unable to access the treatment.
The CMA says that Advanz was able to sustain its progressive price inflation “because liothyronine tablets were among a number of drugs that, although genericised, faced limited or no competition and therefore could sustain repeated price increases… The price increases were not driven by any meaningful innovation or investment, volumes remained broadly stable, and the cost of producing the tablets did not increase significantly.”
In 2006, the NHS spent around £600,000 per year on the drug. By 2016, it was spending more than £30 million.
Advanz says it will appeal the decision.
Subscribe to The Medicine Maker Newsletters
- Competition and Markets Authority (2021). Available at https://bit.ly/3rIXXTw.